<DOC>
	<DOC>NCT01301430</DOC>
	<brief_summary>Investigation on safety, tolerability and efficacy of H-1 parvovirus (H-1PV) in subjects suffering from glioblastoma multiforme.</brief_summary>
	<brief_title>Parvovirus H-1 (ParvOryx) in Patients With Progressive Primary or Recurrent Glioblastoma Multiforme.</brief_title>
	<detailed_description>Investigation on safety, tolerability and efficacy of H-1 parvovirus (H-1PV) in subjects suffering from glioblastoma multiforme. H-1PV will primarily be administered either intratumoral or intravenously. Ten days thereafter a complete or a subtotal tumor resection with a subsequent administration of H-1PV into the walls of the resection cavity will be carried out.</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>Age over or equal to 18 years old, Diagnosis of glioblastoma multiforme, Written informed consent, Recurrent or progressive disease despite previous radio and/or chemotherapy, Indication for complete or subtotal tumor resection, Life expectancy of at least 3 months, Consent for sampling and investigation of biological specimens, Karnofsky Performance Score over or equal to 60, Adequate seizure control, Adequate bone marrow function: neutrophils &gt; 1.5 x 10exp9/L, platelets &gt; 100 x 10exp9/L, hemoglobin &gt; 9.0 g/dL, Adequate liver function: Bilirubin &lt; 2.0 g/dL, ASAT, ALAT, AP, GGT &lt; 3 x ULN, Adequate renal function: Creatinine &lt; 1.8 g/dL, Adequate blood clotting: aPTT &lt; 35 sec, INR &lt; 1.2, Negative serology for HIV, HBV and HCV, Negative BetaHCG test in women of childbearing potential, Commitment to use adequate contraception (in both genders) for up to six months after study entry, Commitment to omit exposure to infants &lt; 18 months of age or immunocompromised individuals for up to 28 day after first administration of IMP. Multifocal disease, Evidence of distant tumor metastases, Contraindications for MRI, Active infection within 5 days prior to the study inclusion, Chemotherapy within 4 weeks prior to the study inclusion, Radiotherapy within 6 weeks prior to the study inclusion, Participation in another interventional trial within the last 30 days, Treatment with antiangiogenic substances within 21 days prior to therapy.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Progressive glioblastoma multiforme</keyword>
	<keyword>Recurrent glioblastoma multiforme</keyword>
	<keyword>Oncolytic virus</keyword>
</DOC>